Related Experiment Video
Updated: Aug 5, 2026
05:41
Synchronous Triplanar Reconstruction Integrated with Color Doppler Mapping for Precise and Rapid Localization of Thyroid Lesions
Published on: February 9, 2024
Thyroid eye disease
Silvia Martina Ferrari1, Francesca Ragusa2, Giusy Elia2
1Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy; Dina Recanati School of Medicine, Reichman University, Herzliya, Israel.
Autoimmunity Reviews
|July 31, 2026
Summary
Thyroid eye disease (TED), an autoimmune condition affecting the eyes in Graves' disease patients, can cause vision loss. New biological drugs show promise for treating TED, offering hope for improved patient outcomes.
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Thyroid eye disease (TED), or Graves' ophthalmopathy, is a frequent autoimmune complication of Graves' disease (GD).
- Affecting retroocular tissues, TED occurs in 30-50% of GD patients and can lead to vision-threatening complications like dysthyroid optic neuropathy.
- The TSH-R/IGF-1R complex is implicated in TED's immunopathogenesis.
Purpose of the Study:
- To provide an updated overview of thyroid eye disease.
- To cover immunopathogenesis, diagnosis, clinical management, and innovative therapies for TED.
- To highlight recent advances in biological drug development for TED.
Main Methods:
- Review of current literature on TED.
- Analysis of immunopathogenesis and clinical presentation.
- Evaluation of existing and emerging therapeutic strategies.
Main Results:
- TED is characterized by ocular redness, eyelid edema, proptosis, and diplopia during its active phase.
- Management includes general measures, thyroid control, local therapies, and immunosuppressants.
- New biological agents like teprotumumab demonstrate efficacy in improving TED symptoms and proptosis.
Conclusions:
- Understanding TED pathophysiology has led to novel therapeutic targets.
- Innovative drugs, including teprotumumab, offer new treatment avenues for TED.
- Ongoing research suggests significant future advancements in managing thyroid eye disease.
Related Concept Videos
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:23The Thyroid Gland
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...